medigraphic.com
ISSN 2520-9078 (Electronic)

2014, Number 1

<< Back Next >>

Revista de Ciencias Médicas de la Habana 2014; 20 (1)

From biomedical research to the clinic: progress of the National Coordinating Center for Clinical Trials

Fors LMM, Costa CN, Viada GC, Pérez RO

Language: Spanish
References: 26
Page: 120-128
PDF size: 150.28 Kb.


ABSTRACT

The National Coordinating Center for Clinical Trials, aimed at the efficiency in the clinical evaluation of medical-pharmaceutical and biotechnology products, as well as Cuban equipments, and also taking into account the importance for all health professionals to know the scientific-technical advances developed since its creation in 1991 until today, in search of the efficiency and safety of the products that are evaluated under strict compliance with international standards and good clinical practice, the present review was conducted, in which it is described the incorporation of the latest global trends and their expansion into the national network. The center also works to raise the scientific and technical level of professionals, for which different training modalities are developed for all the national network of clinical trials. For the realization of this work sources related to the subject were consulted.


REFERENCES

  1. Suzuki C, Jacobson H, Hatschek T, Torkzad MR, Boden K, Erikson-Alm Y, et al. Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics [Internet]. 2008 [citado 20 Jul 2012];28(2). Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/18349443

  2. Vannier MW, Summers RM. Sharing images. Radiology 2003; 228:23–5.

  3. Vannier MW, Staab EV, Clarke LP. Cancer imaging informatics workshop report from the biomedical imaging program of the National Cancer Institute. Acad Radiol [Internet]. 2003 Jul [citado 20 Jul 2012];10(7). Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/12862290

  4. Lazcano E, Salazar E, Gutiérrez P, Angeles A, Hernández A, Viramontes JL. Ensayos clínicos aleatorizados: variantes, métodos de aleatorización, análisis, consideraciones éticas y regulación. Salud Pública Méx [Internet]. 2004 [citado 20 Jul 2012];46(6). Disponible en: http://www.redalyc.org/articulo.oa?id=10646610

  5. Food and Drug Administration. Challenge and Opportunity on the Critical Path to New Medical Technologies [Internet]. Maryland: U.S. Department of Health and Human Services; 2004 [citado 20 Jul 2012]. Disponible en: http://www.who.int/intellectualproperty/documents/en/FDAproposals.pdf .

  6. International cancer technology transfer fellowships (ICRETT) [Internet]. Geneva: UICC; 2013 [citado 20 Jul 2012]. Disponible en: http://www.uicc.org/fellowships/technology-transfer

  7. Ministerio de Salud Pública. Buenas prácticas clínicas. La Habana: MINSAP; 1995.

  8. CIARM. Normas de buenas prácticas clínicas [Internet]. EUA: Grupo Experto de Trabajo de la Conferencia Internacional de Armonización; 1997 [citado 20 Jul 2012]. Disponible en: http://www.fda.gov/downloads/Drugs/.../Guidances/ucm073128.pdf

  9. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects [Internet]. Finland: WMA General Assembly; 2008 [citado 20 Jul 2012]. Disponible en: http://www.wma.net/en/30publications/10policies/b3/17c.pdf

  10. Chang M, Chow S, Pong A. Adaptive designs in clinical research-Issues, opportunities, and recommendations. Journal of Biopharmaceutical Statistics [Internet]. 2006 [citado 20 Jul 2012];16(3). Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/16724486

  11. Posch M, Bauer P, Brannath W. Issues in designing flexible trials. Statist Med [Internet]. 2003 [citado 20 Jul 2012];22(6). Disponible en: http://onlinelibrary.wiley.com/doi/10.1002/sim.1455/abstract

  12. Schuchman M. Comercializing clinical trials risks and benefits of the CRO Boom. N Engl J Med [Internet]. 2007 [citado 20 Jul 2012];357(14). Disponible en: http://ctcorlab.mgh.harvard.edu/shuchman-2007-1203.pdf

  13. Müller H-H, Schäfer H. Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and of classical group sequential procedures. Biometrics [Internet]. Sept 2001 [citado 20 Jul 2012];57. Disponible en: http://www.jstor.org/discover/10.2307/3068429?uid=368052871&uid=3737824&ui d=2&uid=368052821&uid=3&uid=5911496&uid=67&uid=62&sid=2110354471552 3

  14. Tsiatis A, Mehta C. On the inefficiency of the adaptive design for monitoring clinical trials. Biometrika [Internet]. 2003 [citado 20 Jul 2012];90(2). Disponible en: http://www.cytel.com/papers/AdaptiveDesign.pdf

  15. Moses H, Dorsey ER, Matheson HM, Thier SO. Financial anatomy of biomedical research. JAMA [Internet]. Sept 2005 [citado 20 Jul 2012];294(11). Disponible en: http://allhealth.org/briefingmaterials/FinancialAnatomyofBiomedicalResearch- 411.pdf

  16. Hasegawa M, Sone S, Takashima S. Growth rate of small lung cancers detected on mass CT screening. British Journal of Radiology [Internet]. 2000 [citado 20 Jul 2012];73(876). Disponible en: http://www.birpublications.org/doi/pdf/10.1259/bjr.73.876.11205667

  17. Lang T. Adaptive trial design: could we use this approach to improve clinical trials in the field of global health?. Am J Trop Med Hyg [Internet]. Dec 2011 [citado 20 Jul 2012];85(6). Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3225172/

  18. Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. J Pharm Sci [Internet]. 1992 [citado 20 Jul 2012];81(6). Disponible en: http://onlinelibrary.wiley.com/doi/10.1002/jps.2600810630/abstract

  19. Hann LE, Winston CB, Brown KT, Akhurst T. Diagnostic Imaging Approaches and Relationship to Hepatobiliary Cancer Staging and Therapy. Seminars in Surgical Oncology [Internet]. Oct 2000 [citado 20 Jul 2012];19(2). Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/11126385

  20. FDA. Critical Path Opportunities Report [Internet]. 2006 [citado 20 Jul 2012]. Disponible en: http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiati ve/CriticalPathOpportunitiesReports/UCM077254.pdf

  21. Zubrod CG, Schneiderman SM, Frei E III, Brindley C, Gold GL, Schnider B, et al. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and thiophosphamide. J Chronic Dis 1960;11:7–33.

  22. Gehan E, Schneidermann M. Historical and methodological developments in clinical trials at the National Cancer Institute. Stat Med [Internet]. 1990 [citado 20 Jul 2012];9(8). Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/2218190

  23. Palmer MK. WHO Handbook for Reporting Results of Cancer Treatment. Br J Cancer [Internet]. Mar 1982 [citado 20 Jul 2012];45(3). Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2010938/pdf/brjcancer00438- 0161b.pdf

  24. Mazumdar M, Smith A, Schwartz LH. A statistical simulation study finds discordance between WHO criteria and RECIST guideline. J Clin Epidemiol [Internet]. Apr 2004 [citado 20 Jul 2012];57(4). Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/15135836

  25. Backgrounder. How new drugs move through the development and approval process [Internet]. Boston: Food and Drug Administration; 2001 [citado 20 Jul 2012]. Disponible en http://csdd.tufts.edu/files/uploads/how_new_drugs_move.pdf

  26. Weissleder B, W. R. In Vivo Imaging of Gene Expression. Academic Radiology 2001;8:15–23.




2020     |     www.medigraphic.com